Company intelligence / Profile preview

Galux

Ownership: Private
Development stage: Other

Overview

Galux has achieved a significant milestone by demonstrating that its proprietary AI platform can successfully design de novo antibodies with high specificity and affinity against six diverse therapeutic targets. Its lead molecules have shown binding affinities comparable to or better than established drugs like atezolizumab in preclinical assays. The technology is validated through multiple industry and academic collaborations but there are no reported clinical trial results yet.

Therapeutic areas: OncologyMetabolic DisordersImmunology
Modalities: AntibodyPeptidesSmall moleculeProtein
Industry: Biotech

Drug pipeline

3 assets

Galux-IL-18-antibody (AI-designed)

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Validated through at least fifteen industry and academic collaborations; specific partners not named in public sources as of June 2025.

Beyond the preview

Go deeper on Galux.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galux.

Explore the full profile